Early interventions at art initiation to reduce the HIV-1 reservoir and enhance adaptive immune responses - increasing efforts are being made to understand whether early intervention after HIV-1…
Active Grant Awarded Last action
- Award ID
- R01AI184285
- Recipient
-
The Trustees Of The University Of Pennsylvania UEI GM1XX56LEP58
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,082,903
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 45% complete
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from USAspending.gov.
Description
Early interventions at art initiation to reduce the HIV-1 reservoir and enhance adaptive immune responses - increasing efforts are being made to understand whether early intervention after HIV-1 infection can enable long- term viral control and reduction of the viral reservoir through the preservation of HIV-1-specific immune responses. Recently, the pioneering eclear phase 1B/2A clinical trial led by MPI SØGAARD, found that administration of the HIV-ENV specific broadly neutralizing antibody (BNAB) 3BNC117 at antiviral therapy (art) initiation enhanced CD8+ T cell viral immunity and enabled viral control amongst participants harboring 3BNC117-sensitive viruses. However, the mechanisms underlying this outcome remain largely unknown. Understanding the goal of this collaborative R01 (M BETTS, upenn, B jones, weill-cornell university, and O. SØGAARD, aarhus university) is to define the mechanisms underlying this protective outcome in order to inform future development of targeted immunotherapy at art initiation as an HIV cure strategy. We hypothesize that the partial success of eclear can be defined in terms of both specific mechanisms of efficacious CD8+ T-cell responses and of the features selected in remaining reservoir-harboring cells. We will address this hypothesis in three integrated aims using samples directly from the eclear study. In aim 1, we will define phenotypic, functional, and transcriptomic features of the adaptive T cell immune responses that are modulated by BNAB treatment at art initiation (SØGAARD). In aim 2, we will define how the HIV reservoir is differentially modulated after prolonged art treatment and within post-therapy viral controllers VS. Non- controllers who received 3BNC117 (BETTS). In aim 3, we will define the ability of CD8+ T cells from eclear participants who did or did not exhibit post-art control to mediate viral control in vivo using a novel humanized mouse model. In addition, we will modulate CD8+ T cell functions within this system to uncover specific control mechanisms. The anticipated outcomes of our project are I) a comprehensive characterization of the immunologic and reservoir features associated with the partial efficacy of eclear, II) validation of underlying mechanisms, to guide future iterations of clinical interventions at the time of art initiation.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $545,816 | |
| Amendment | $0 | |
| Amendment | $149,150 | |
| Amendment | $545,151 | |
| Original award | $694,301 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Aarhus Universitet | $149,150 | |
| Weill Medical College Of Cornell University | $195,657 | |
| Weill Medical College Of Cornell University | $195,657 | |
| Weill Medical College Of Cornell University | $185,273 | |
| Aarhus Universitet | $143,459 |
Quick answers
Who received award R01AI184285?
R01AI184285 was awarded to The Trustees Of The University Of Pennsylvania by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 19, 2024.
How much is award R01AI184285 worth?
$2,082,903 has been obligated on R01AI184285.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award